The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.
about
The safety of long-acting ß2-agonists in the treatment of stable chronic obstructive pulmonary diseaseLong-acting beta2-agonists for chronic obstructive pulmonary diseaseβ(2) -adrenoceptor agonists: current and future directionEfficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysisUpdate on pharmaceutical and minimally invasive management strategies for chronic obstructive pulmonary disease.Safety of indacaterol in the treatment of patients with COPD.Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPDPharmacological treatment of COPD.Budesonide/formoterol Turbuhaler®: a review of its use in chronic obstructive pulmonary disease.A-kinase anchoring proteins: cAMP compartmentalization in neurodegenerative and obstructive pulmonary diseases.Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.Economic evaluations of fluticasone-propionate/salmeterol combination therapy for chronic obstructive pulmonary disease: a review of published studies.The importance of β2-agonists in myocardial infarction: Findings from the Eastern Danish Heart Registry.Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis.Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B.
P2860
Q22305858-1B69A36B-546D-47FC-B94F-2F866F26F85DQ24197467-FC1BBC45-0522-4C2C-ADD1-B5F08691B1BAQ24604047-E4A40D64-9A15-4597-B374-F0FC9573CE20Q26744161-D92C6676-0F2B-4A69-981A-DEC3C57DD208Q35028812-5C4B31E7-38F5-4CD2-B74D-C459A1CB8A10Q35268351-D31E9D5F-C303-4FB4-9C3B-DF61F6FCDC85Q37177278-EE27DA69-EF8D-44CB-B43B-7D8584755DA4Q37614090-4631F1C8-002E-4FD6-B085-81CA27A024D5Q37924598-514BAD4B-370F-420F-A312-7C5F129BB1A4Q37982436-55D5D063-AE31-4B87-92E4-3E3ABDEB3143Q38240756-AEC2D2E2-DA7C-4538-A6BB-E6B5B5001748Q38345525-802C5FFF-5E2A-439F-9BDF-5D304B7CC892Q38721028-C6523C05-8E0F-4F56-9821-2FDCE567D8B3Q39183200-F9D5B978-66C7-42A5-B081-76C1DE02FFEBQ39399389-A1D85E2E-344D-48AB-BF5C-D7EDB9681960Q43686215-B3B8E890-FCD5-44E7-B39A-5199FF1ED485Q52805734-5641C6C0-1CEC-480A-9EC9-CB2800A617E0
P2860
The effects of long-acting bronchodilators on total mortality in patients with stable chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effects of long-acting bro ...... obstructive pulmonary disease.
@en
The effects of long-acting bro ...... obstructive pulmonary disease.
@nl
type
label
The effects of long-acting bro ...... obstructive pulmonary disease.
@en
The effects of long-acting bro ...... obstructive pulmonary disease.
@nl
prefLabel
The effects of long-acting bro ...... obstructive pulmonary disease.
@en
The effects of long-acting bro ...... obstructive pulmonary disease.
@nl
P2093
P2860
P31
P921
P356
P1433
P1476
The effects of long-acting bro ...... obstructive pulmonary disease.
@en
P2093
Agnes Kliber
Larry D Lynd
P2860
P2888
P356
10.1186/1465-9921-11-56
P577
2010-05-11T00:00:00Z
P5875
P6179
1029661131